Cardiovascular Health · Article 02

Cholesterol Explained

What cholesterol is, why LDL matters, and what the evidence shows about managing it — in plain English.

9 minute read
Evidence-based
Sources: NICE · The Lancet · JAMA · NHS · WHO · ESC
⚕️

Health education — not medical advice. Anything personally relevant is a conversation for you to have with your GP or healthcare professional.

1

What is it?

Cholesterol is a fatty substance found naturally in the blood. Despite its reputation, the body needs it — it plays an essential role in building healthy cells, producing hormones, and absorbing fat-soluble vitamins. The problem arises when there is too much of certain types circulating in the bloodstream.

Cholesterol is carried through the blood by proteins, forming particles called lipoproteins. There are three key types:

TypeCommon nameWhat it does
LDL (low-density lipoprotein) "Bad" cholesterol Deposits cholesterol into artery walls, forming plaques that narrow and harden arteries — the main driver of heart attack and stroke risk
HDL (high-density lipoprotein) "Good" cholesterol Carries cholesterol away from artery walls back to the liver, where it is broken down and removed — a protective process
Non-HDL cholesterol Total minus HDL The broader measure of all potentially harmful fats — now the preferred treatment target in UK clinical guidelines (NICE NG238)

Raised cholesterol causes no symptoms. The only way to establish lipid levels is through a blood test — which is why it is categorised alongside hypertension as a clinically silent cardiovascular risk factor.

📖 Key Terms

Cardiovascular disease (CVD)An umbrella term for conditions affecting the heart and blood vessels, including heart attack, stroke, heart failure, and coronary heart disease — the leading cause of death in the UK.
Ischaemic heart diseaseNarrowing or blockage of the arteries supplying the heart, reducing blood flow. The most common cause of heart attacks. Also called coronary heart disease (CHD).
AtherosclerosisThe gradual build-up of fatty plaques (atheroma) inside artery walls, causing them to narrow and harden. The underlying process behind most heart attacks and strokes.
TriglyceridesAnother type of fat found in the blood. Elevated triglycerides, often seen alongside raised cholesterol, further increase cardiovascular risk.
StatinA class of medication that lowers LDL cholesterol by reducing production in the liver. The most widely prescribed cholesterol-lowering treatment worldwide.
Familial hypercholesterolaemia (FH)An inherited condition causing very high LDL cholesterol from birth. Affects approximately 1 in 250 UK adults — most are undiagnosed. Untreated FH significantly increases the risk of early coronary heart disease.
mmol/LMillimoles per litre — the unit used in the UK to measure cholesterol and other blood lipid levels.
EzetimibeA non-statin cholesterol-lowering medication that works by reducing cholesterol absorption in the small intestine. Often added to statin therapy when LDL targets are not reached.

Quick Visual Summary

A slide-by-slide visual overview of this article. Use the ← → arrow keys on your keyboard, or tap the dots at the bottom of the panel to move between slides.

2

Why does it matter?

59%
of adults in England have raised total cholesterol
Defined as ≥5 mmol/L under NHS guidelines. Globally, 39% of adults are affected — rates are highest in Europe and North America.1
~22%
reduction in major cardiovascular events
Associated with each 1 mmol/L reduction in LDL cholesterol — a consistent finding across large-scale randomised trial evidence.2
1 in 250
UK adults has familial hypercholesterolaemia
An inherited condition causing elevated LDL from birth. Most remain undiagnosed. Untreated, it carries a greatly elevated risk of premature coronary heart disease.5
14,000
preventable events in 3 years
NHS England estimates this many heart attacks, strokes and premature deaths could be prevented in three years if 90% of people with cardiovascular disease were identified and treated.6

High LDL cholesterol directly drives the narrowing and hardening of arteries — the process that underlies most heart attacks and strokes. The clinical significance of this relationship is supported by decades of randomised trial data and further confirmed by genetic studies showing that naturally lower LDL from birth is associated with proportionally reduced lifetime cardiovascular risk.

Like hypertension, raised cholesterol produces no symptoms. It is a laboratory finding, not a clinical one — which is why cholesterol testing in the context of routine cardiovascular risk assessment is an established part of UK healthcare practice.

3

What your doctor might do

Cholesterol testing

Cholesterol is measured through a simple blood test — typically as part of an NHS Health Check (offered to everyone aged 40–74 in England every five years), or when cardiovascular risk factors are present that warrant earlier assessment. The test measures total cholesterol, HDL, and triglycerides, from which non-HDL and LDL are calculated.

Under current UK guidelines (NICE NG238), fasting is not routinely required before a cholesterol blood test, though specific clinical circumstances may affect this.

Understanding the results

Cholesterol numbers are interpreted in the context of overall cardiovascular risk — not in isolation. General targets for most healthy adults in UK practice are:

MeasureGeneral target (healthy adults)
Total cholesterolBelow 5.0 mmol/L
Non-HDL cholesterolBelow 4.0 mmol/L
LDL cholesterolBelow 3.0 mmol/L
HDL cholesterol (men)Above 1.0 mmol/L
HDL cholesterol (women)Above 1.2 mmol/L

For those with established cardiovascular disease, treatment targets are lower — below 2.0 mmol/L for LDL, or below 2.6 mmol/L for non-HDL, as set out in NICE NG238.4 Overall risk is assessed using a validated risk calculator (see the risk calculators section of helf.school).

Management — lifestyle and medication

For many people, lifestyle measures produce meaningful improvements in cholesterol profile — reducing saturated fat intake, regular aerobic exercise, weight management, reduced alcohol intake, and smoking cessation are all clinically recognised as beneficial for lipid levels.

Where medication is indicated, statins are the most evidenced first-line treatment. NICE NG238 identifies atorvastatin as first-line for primary prevention in those with a 10-year cardiovascular risk of 10% or more. For those with established cardiovascular disease, the dose is higher. Where statin therapy is not tolerated, ezetimibe and other agents are available options.4

Cholesterol levels are typically rechecked around three months after starting or adjusting treatment to assess the response.

4

What the research shows

LDL reduction and cardiovascular risk — the CTT Collaboration
The Lancet · 2005
Cholesterol Treatment Trialists' Collaboration · The Lancet · 2005 · 14 trials · 90,000+ participants
Key finding
~20%
lower risk of major cardiovascular events
per 1 mmol/L reduction in LDL cholesterol — regardless of starting level or other risk factors
This meta-analysis of 14 randomised controlled trials involving more than 90,000 participants found that each 1 mmol/L reduction in LDL cholesterol cut the risk of major cardiovascular events — including heart attack and stroke — by around one fifth. The benefit was largely consistent regardless of a person's starting cholesterol level, age, sex, or other risk factors — establishing LDL reduction as a robust treatment target in cardiovascular risk management.
Cholesterol Treatment Trialists' Collaboration. The Lancet. 2005. PubMed: 16214597
LDL lowering benefits extend to lower-risk groups — CTT 2012
The Lancet · 2012
Cholesterol Treatment Trialists' Collaboration · The Lancet · 2012 · 27 trials · 175,000 participants
Key finding
11
fewer major vascular events per 1,000 people
over 5 years per 1 mmol/L LDL reduction — even in lower cardiovascular risk groups
This larger follow-up meta-analysis extended the CTT findings to lower-risk populations. Even in people at lower cardiovascular risk, each 1 mmol/L reduction in LDL produced approximately 11 fewer major vascular events per 1,000 people over five years. The proportional reduction in risk was consistent across the full range of cardiovascular risk, supporting a lower-threshold approach to treatment in those with elevated lipids.
Cholesterol Treatment Trialists' Collaboration. The Lancet. 2012. PubMed: 22607822
Supplements vs statins — the SPORT trial
JACC · 2023
Laffin et al · Journal of the American College of Cardiology · 2023
Key finding
38%
LDL reduction from low-dose statin
vs no significant LDL reduction from fish oil, garlic, cinnamon, turmeric, plant sterols, or red yeast rice
The SPORT trial directly compared low-dose rosuvastatin against six widely used supplements (and placebo) in a randomised controlled design. The results:
TreatmentLDL change vs placebo
Rosuvastatin (statin)~38% reduction
Fish oilNo significant reduction
GarlicNo significant reduction
CinnamonNo significant reduction
TurmericNo significant reduction
Plant sterolsNo significant reduction
Red yeast riceNo significant reduction
The 2025 ESC/EAS dyslipidaemia guidelines reviewed all available evidence and reached the same conclusion — no supplement or vitamin was found to be both safe and effective for reducing LDL cholesterol or lowering cardiovascular risk.
Laffin et al. J Am Coll Cardiol. 2023. DOI: 10.1016/j.jacc.2022.10.013 · ESC/EAS Focused Update 2025.
NICE guideline NG238 — cardiovascular disease: risk assessment and reduction
NICE · 2023
National Institute for Health and Care Excellence · NG238 · Updated December 2023
UK treatment threshold
10%
10-year cardiovascular risk — threshold for offering statin therapy
for primary prevention · atorvastatin 20mg first line · higher-risk individuals: atorvastatin 80mg with LDL target below 2.0 mmol/L
NICE NG238 is the primary UK clinical framework for lipid management and cardiovascular risk reduction. It recommends atorvastatin 20mg for primary prevention in those with a 10-year cardiovascular risk of 10% or more, and atorvastatin 80mg for secondary prevention in those with established cardiovascular disease. Treatment targets for secondary prevention are LDL below 2.0 mmol/L (or non-HDL below 2.6 mmol/L). Lifestyle measures are an integral component of management at all levels of risk.
🔑 Putting it all together

Cholesterol is one of the most common and most consequential modifiable cardiovascular risk factors in the UK. Around 59% of adults in England have raised total cholesterol — and yet, like blood pressure, it produces no symptoms and is detectable only through testing. The clinical significance of LDL cholesterol as the primary driver of atherosclerosis is supported by large-scale randomised trial evidence and confirmed by genetic data showing that lower lifetime LDL exposure translates to lower lifetime cardiovascular risk.

The evidence for statin therapy is among the most robust in cardiovascular medicine. The SPORT trial confirmed what clinical guidelines have long reflected — no supplement provides the LDL reduction that a statin delivers. Lifestyle measures are genuinely effective as part of a broader approach, and for some people are sufficient at lower risk levels.

Understanding what cholesterol is, what the different numbers mean, and how the evidence supports different management approaches is the foundation for any informed conversation about lipid levels — whether at an NHS Health Check, following a blood test result, or after a diagnosis of cardiovascular disease. That conversation belongs with a GP or healthcare professional.

About the author — Dr Paul spent over twenty years as an NHS GP before retiring in 2019. helf.school exists to give every person access to clear, honest, evidence-based health education. Read more about Dr Paul →

References

1
NHS Digital. Health Survey for England 2021. NHS Digital, 2022. World Health Organization. Global Health Observatory — Raised cholesterol. WHO, 2023.
2
Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267–1278.
3
Cholesterol Treatment Trialists' Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease. The Lancet. 2012;380(9841):581–590.
4
National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238. Updated December 2023.
5
National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management. NICE guideline CG71. 2008 (last reviewed 2023).
6
NHS England. Improving Lipid Management to Reduce Cardiovascular Disease and Save Lives. NHS England, 2023.
7
Laffin LJ et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol. 2023;81(7):690–702.